# Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

> **NCT04832971** · PHASE2 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 204 (actual)

## Conditions studied

- Mixed Dyslipidemia

## Interventions

- **DRUG:** ARO-ANG3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04832971
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-28
- **Primary completion:** 2022-08-30
- **Final completion:** 2024-09-25
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832971, "Study of ARO-ANG3 in Adults With Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04832971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*